Paris, Amsterdam, March 2, 2023
Following the request filed by Unibail-Rodamco-Westfield Group (URW) with Euronext as announced on February 9, 2023, the Group has obtained the approval of the Euronext Listing Board on February 28, 2023 to change its market of reference from Euronext Amsterdam to Euronext Paris and delist the URW stapled shares from Euronext Amsterdam, while maintaining their listing on Euronext Paris.
Pursuant to the timing validated by Euronext, URW announces that:
- The change of its market of reference from Euronext Amsterdam to Euronext Paris will be effective on April 14, 2023;
- The last day of trading on Euronext Amsterdam will be April 27, 2023;
- The delisting from Euronext Amsterdam will be effective on April 28, 2023.
As part of these changes, URW will no longer be represented in the Dutch AEX25 index as from March 9, 2023. These changes will not impact URW’s inclusion in the CAC40 index.
The delisting from Euronext Amsterdam would not affect the liquidity of the stapled shares nor have any impact on trading, URW’s structure (including the stapled share principle) or the ISIN code (FR0013326246) of the Group. All transactions currently carried out at Euronext are and will remain processed through the Euronext single order book.
A notice will also be published by Euronext in due course.
For further information, please contact:
VP, Chief of Staff to the CEO
+1 424 303 1948
Cornelia Schnepf – Finelk
+44 7387 108 998
Sonia Fellmann – PLEAD
+33 6 27 84 91 30
Molly Morse – Kekst CNC
+ 1 212 521 4826
Unibail-Rodamco-Westfield is an owner, developer and operator of sustainable, high-quality real estate assets in the most dynamic cities in Europe and the United States.
The Group operates 78 shopping centres in 12 countries, including 43 which carry the iconic Westfield brand. These centres attract over 800 million visits annually and provide a unique platform for retailers and brands to connect with consumers. URW also has a portfolio of high-quality offices, 10 convention and exhibition venues in Paris, and a €3 Bn development pipeline of mainly mixed-use assets. Currently, its €52 Bn portfolio is 87% in retail, 6% in offices, 5% in convention and exhibition venues, and 2% in services (as at December 31, 2022).
URW is a committed partner to major cities on urban regeneration projects, through both mixed-use development and the retrofitting of buildings to industry-leading sustainability standards. These commitments are enhanced by the Group’s Better Places 2030 agenda, which strives to make a positive environmental, social and economic impact on the cities and communities where URW operates.
URW’s stapled shares are listed on Euronext Amsterdam and Euronext Paris (Ticker: URW), with a secondary listing in Australia through Chess Depositary Interests. The Group benefits from a BBB+ rating from Standard & Poor’s and from a Baa2 rating from Moody’s.
For more information, please visit www.urw.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz
Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release
Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023
Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse
Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023
PARKEN Sport & Entertainment A/S - Bestyrelsesændring21.3.2023 15:24:14 CET | pressemeddelelse
William Kvist genopstiller ikke til bestyrelsen på selskabets ordinære generalforsamling den 21. april 2023. William Kvist har været en del af bestyrelsen siden 2019 og var i en periode også fungerende sportslig leder i F.C. København. Vedhæftet fil 09-2023 Bestyrelsesændring
Forløb af ordinær generalforsamling 2023, 2. meddelelse21.3.2023 15:14:40 CET | pressemeddelelse
Forløb af ordinær generalforsamling 2023, 2. meddelelse Vedhæftet fil Forløb af ordinær generalforsamling 2023, meddelelse 2